Allergan Sues Watson Over Sanctura Incontinence Drug

Allergan Inc. (AGN), the maker of wrinkle- smoothing Botox, sued Watson Pharmaceuticals Inc., alleging infringement of a U.S. patent for Sanctura XR, a prescription medicine used to treat overactive bladder.

Allergan, and business partners Endo Pharmaceuticals Solutions Inc. (ENDP) and Supernus Pharmaceuticals Inc. (SUPN), contend in a federal court complaint that Watson plans to market a generic version of Sanctura before the 2008 patent expires in 2025.

“Plaintiffs will be irreparably harmed by Watson Pharmaceuticals’ infringing activities” unless stopped by a judge, according to court papers filed yesterday in Wilmington, Delaware.

Irvine, California-based Allergan, with $4.4 billion in total sales last year, and Endo of Chadds Ford, Pennsylvania, with $1.26 billion in 2008 sales, co-market Sanctura in the U.S., according to the lawsuit. Rockville, Maryland-based Supernus, the closely held patent owner, bought out Shire Laboratories in 2005.

Besides an injunction against generic sales, Allergan and its partners seek unspecified damages and a declaration that the patent is infringed.

Patty Eisenhaur, a Watson spokeswoman, didn’t immediately return a call seeking comment on the lawsuit.

Corona, California-based Watson, with $2.53 billion in sales last year, fell 2 cents to $33.50 at 4:29 p.m. in New York Stock Exchange composite trading.

Allergan rose 6 cents to $45.96 on the NYSE. Endo fell 13 cents to $17.64 in Nasdaq Stock Market trading.

The case is Allergan Inc. v. Watson Pharmaceuticals Inc. (WPI), 09CV511, U.S. District Court, District of Delaware (Wilmington).

To see the patent, click: 7,410,978.

To contact the reporter on this story: Phil Milford in Wilmington, Delaware, at

To contact the editor responsible for this story: David E. Rovella at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.